Important Information for Intellia Therapeutics, Inc. Investors: Securities Class Action Lawsuit Filed
New York, NY – March 18, 2025
Levi & Korsinsky, LLP, a premier securities litigation firm, has announced that a class action securities lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors in Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA).
Class Definition
The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024, and January 8, 2025. The complaint alleges that Intellia and certain of its top executives made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and financial condition.
Allegations
According to the complaint, the defendants made false and/or misleading statements and/or failed to disclose that:
- Intellia’s CRISPR-Cas9 gene editing technology was not as advanced as represented;
- The Company was experiencing significant manufacturing issues;
- There were delays in the development of Intellia’s lead product, NTLA-2001;
- The Company’s financial statements were not accurate;
Impact on Intellia Therapeutics Investors
If you invested in Intellia Therapeutics, Inc. between July 30, 2024, and January 8, 2025, you may be entitled to recover your losses, including damages. To determine eligibility and learn how to take part in the case, please contact Levi & Korsinsky, LLP by email at [email protected] or call 212-363-7500. Levi & Korsinsky has extensive experience in prosecuting securities class actions and other complex litigation.
Impact on the World
The securities lawsuit against Intellia Therapeutics, Inc. is significant because it raises concerns about the accuracy of the Company’s public statements and the potential for fraud in the gene editing industry. The lawsuit could lead to increased scrutiny of other companies in the sector and potentially impact investor confidence in the industry as a whole. Additionally, if the allegations are proven true, it could result in significant financial losses for Intellia and its shareholders.
Conclusion
Investors in Intellia Therapeutics, Inc. who were adversely affected by the Company’s alleged securities fraud between July 30, 2024, and January 8, 2025, have the opportunity to recover their losses through the class action securities lawsuit filed against the Company. Levi & Korsinsky, LLP encourages investors to contact the firm to learn more about their rights and potential remedies. The lawsuit could have far-reaching implications for the gene editing industry and investor confidence in the sector.
As the investigation into Intellia Therapeutics, Inc.’s business practices continues, it is essential for investors to stay informed and protect their investments. For more information, please visit the firm’s website at www.zlk.com.
